With 20 Players Swamping Generic Topamax Market in U.S., Prices Set To Crash Below 95 Percent
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The price of Ortho McNeil Janssen's anti-epileptic brand Topamax (topiramate) is set to crash with the entry of as many as 20 generic versions of the product in the U.S. market from the first day of the patent expiry